A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation

NCT06556394 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG: RAG-17
DRUG: Placebo

Sponsor

Ractigen Therapeutics.